Regulation
OncoSil Medical secures TGA approval for pancreatic cancer device
OncoSil Medical received approval from Australia's Therapeutic Goods Administration (TGA) for its OncoSil device, a pancreatic cancer treatment indicated for use with gemcitabine-based chemotherapy in locally advanced pancreatic cancer (LAPC). The clearance expands the device's regulatory footprint in the Asia-Pacific region.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network